AstraZeneca will partner with Bicycle Therapeutics to develop respiratory, cardiovascular, and metabolic disease treatments based on Bicycle’s proprietary bicyclic peptide (Bicycle®) product platform through a collaboration that the Cambridge, U.K., startup said today could generate for it more than $1 billion.
Under the collaboration, Bicycle has agreed to identify Bicycle bicyclic peptides for an undisclosed number of targets specified by AstraZeneca. The pharma giant has agreed to oversee further development and product commercialization.